Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (201-210 of 322) with videos related to

Pageof 33
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Molecular Cancer Therapeutics|March 4, 2026
Targeting menin in T-lineage acute lymphoblastic leukemiaKathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, et al.
Blood Advances|March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaZachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The Lancet. Oncology|August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyJean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Leukemia & Lymphoma|October 12, 2020
Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologistsKah Poh Loh, Maya Abdallah, Sindhuja Kadambi, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Nature Cancer|May 19, 2022
Acute lymphoblastic leukemia displays a distinct highly methylated genomeSara Hetzel, Alexandra L Mattei, Helene Kretzmer, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Pageof 33

Showing results (201-210 of 322) with videos related to

Sort By:
Pageof 33
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Molecular Cancer Therapeutics|March 4, 2026
Targeting menin in T-lineage acute lymphoblastic leukemiaKathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, et al.
Blood Advances|March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaZachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood Advances|February 25, 2020
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801Guido Marcucci, Susan Geyer, Kristina Laumann, et al.
The Lancet. Oncology|August 23, 2015
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyJean-Pierre J Issa, Gail Roboz, David Rizzieri, et al.
Leukemia & Lymphoma|October 12, 2020
Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologistsKah Poh Loh, Maya Abdallah, Sindhuja Kadambi, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Nature Cancer|May 19, 2022
Acute lymphoblastic leukemia displays a distinct highly methylated genomeSara Hetzel, Alexandra L Mattei, Helene Kretzmer, et al.
Blood|June 5, 2010
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808Jonathan E Kolitz, Stephen L George, Guido Marcucci, et al.
Pageof 33